Speaker
Ryan Kelly, Director of Business Development
Anti-Idiotypic antibodies (anti-Id) are critical assay reagents used in PK/ADA assays for therapeutic biologics entering clinical trials. Ensuring the timely readiness of high-quality, assay-ready anti-Id is a top-priority task for all bioanalytical groups. In this webinar, the Abveris team will discuss how to de-risk anti-Id discovery in terms of screening platform and strategy selection. In the second of this two-part webinar series, the following topics will be discussed:
1. Challenges for anti-Id discovery for cell-based biologics
2. Case study of an anti-Id discovery campaign for a CAR-T product
Overview of screening technologies for anti-Id antibodies discovery.
Dos and don'ts when planning and designing anti-Id discovery campaigns
Case studies of hybridoma-based and Beacon-based anti-Id campaigns targeting therapeutic biologics
Click the link below to schedule a meeting with one of our scientists!
